Since the NF-κB2 pathway is typically activated by BAFFR (33), we tested the processing of NF-κB2 by stimulating B-lymphoblasts from two BAFFR+ pre-B ALL patients and from one BAFFR− common B-ALL patient with BAFF overnight in a dose-dependent manner. Here, TNFSF13B is linked to acute lymphoblastic leukemia.